Medtronic plc (MDT) FY2025 YTD Q3 P&L / Income Statement

Medtronic plc (MDT) FY2025 YTD Q3 P&L / Income Statement

Income statement for 2024-04-27 through 2025-01-24. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

24,610,000,000 US dollars

Cost of products sold, excluding amortization of intangible assets

8,485,000,000 US dollars

Gross profit (calculated)

16,125,000,000 US dollars

Operating costs, net of other operating income (calculated)

11,606,000,000 US dollars

Operating profit

4,519,000,000 US dollars

Other income (expense), net (calculated)

negative 152,000,000 US dollars

Income before income taxes

4,367,000,000 US dollars

Income tax provision

737,000,000 US dollars

Net income

3,630,000,000 US dollars

Cardiovascular

9,145,000,000 US dollars

Neuroscience

7,226,000,000 US dollars

Medical Surgical

6,196,000,000 US dollars

Diabetes

2,027,000,000 US dollars

Other operating segment

106,000,000 US dollars

Research and development expense

2,048,000,000 US dollars

Selling, general, and administrative expense

8,129,000,000 US dollars

Amortization of intangible assets

1,243,000,000 US dollars

Restructuring charges, net

120,000,000 US dollars

Certain litigation charges, net

104,000,000 US dollars

Other operating (income) expense, net

negative 38,000,000 US dollars

Revenue before reconciliation (calculated)

24,700,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Other Adjustments

negative 90,000,000 US dollars. Reported reconciliation to consolidated revenue.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
• Of which attributable to Medtronic plc: $3.61 B; to noncontrolling interests: $24.00 M.